Theralink Technologies Inc.

As of December 31, 2023, Theralink Technologies Inc. has 6.15B shares outstanding.

As of December 31, 2023, Theralink Technologies Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -41.59, indicating conservative leverage, while an interest coverage ratio of -0.39 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -536.39, reflecting losses generated across the asset base. The company generates approximately 36,311.43 in revenue per employee across its workforce of 17.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2023, Theralink Technologies Inc. generated 635,450.00 in revenue and converted that into -13.50M in net income, yielding earnings per share of 0.00. EBITDA reached -7.75M, while operating income came in at -7.71M.

As of December 31, 2023, Theralink Technologies Inc. holds 24,270.00 in cash and equivalents against 23.76M in total debt, resulting in a net debt position of 22.56M. Total book value stands at -57.12M, with working capital of -57.53M providing operational flexibility.

Theralink Technologies Inc. produced -4.96M in operating cash flow over the twelve months ended December 31, 2023. After subtracting -155,400.00 in capital expenditures, free cash flow totaled -5.12M - equivalent to 0.00 per share.

Over the twelve months ended December 31, 2023, Theralink Technologies Inc. posted a gross margin of 73.50, reflecting its pricing power and cost economics. The operating margin of -1,213.62 and net profit margin of -2,124.13 provide insight into operational efficiency.

Theralink Technologies Inc. 's most recent stock split took place on September 13, 2019 with a 750:1 split ratio.